NextCure (NXTC) Competitors $4.89 -0.07 (-1.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.84 -0.05 (-1.02%) As of 08/1/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NXTC vs. ATNM, PDSB, ANVS, DTIL, SNTI, NRXP, ZIVO, XCUR, IPSC, and JSPRShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Actinium Pharmaceuticals (ATNM), PDS Biotechnology (PDSB), Annovis Bio (ANVS), Precision BioSciences (DTIL), Senti Biosciences (SNTI), NRx Pharmaceuticals (NRXP), ZIVO Bioscience (ZIVO), Exicure (XCUR), Century Therapeutics (IPSC), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry. NextCure vs. Its Competitors Actinium Pharmaceuticals PDS Biotechnology Annovis Bio Precision BioSciences Senti Biosciences NRx Pharmaceuticals ZIVO Bioscience Exicure Century Therapeutics Jasper Therapeutics NextCure (NASDAQ:NXTC) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends. Which has more risk and volatility, NXTC or ATNM? NextCure has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.32, meaning that its stock price is 132% less volatile than the S&P 500. Do insiders & institutionals believe in NXTC or ATNM? 42.7% of NextCure shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 17.9% of NextCure shares are held by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is NXTC or ATNM more profitable? NextCure's return on equity of -70.16% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NextCureN/A -70.16% -58.10% Actinium Pharmaceuticals N/A -100.85%-47.89% Which has higher earnings & valuation, NXTC or ATNM? Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNextCureN/AN/A-$55.65M-$21.13-0.23Actinium PharmaceuticalsN/AN/A-$48.82M-$1.47-1.10 Do analysts recommend NXTC or ATNM? NextCure presently has a consensus price target of $25.50, suggesting a potential upside of 421.47%. Actinium Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 148.45%. Given NextCure's higher possible upside, equities analysts clearly believe NextCure is more favorable than Actinium Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media prefer NXTC or ATNM? In the previous week, NextCure and NextCure both had 1 articles in the media. NextCure's average media sentiment score of 0.48 beat Actinium Pharmaceuticals' score of 0.00 indicating that NextCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryNextCure beats Actinium Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.27M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-0.2317.6228.6723.80Price / SalesN/A179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book0.178.508.275.55Net Income-$55.65M-$55.06M$3.24B$259.03M7 Day Performance-20.75%-3.98%-3.69%-4.59%1 Month Performance-4.86%9.59%4.33%4.46%1 Year Performance-74.53%6.72%25.95%18.03% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.5767 of 5 stars$4.89-1.4%$25.50+421.5%-74.7%$13.27MN/A-0.2390News CoverageUpcoming EarningsGap DownATNMActinium Pharmaceuticals1.9811 of 5 stars$1.69-1.2%$4.00+136.7%-75.6%$52.72MN/A-1.2230News CoveragePDSBPDS Biotechnology1.6266 of 5 stars$1.15flat$9.00+682.6%-66.3%$52.57MN/A-1.2220ANVSAnnovis Bio2.008 of 5 stars$2.53-4.5%$18.00+611.5%-72.5%$51.64MN/A-1.173DTILPrecision BioSciences4.0826 of 5 stars$4.65+0.9%$47.00+910.8%-51.7%$51.12M$68.70M-2.31200Upcoming EarningsSNTISenti Biosciences1.7473 of 5 stars$1.98+1.5%$8.50+329.3%-22.2%$50.86M$2.56M-0.184NRXPNRx Pharmaceuticals2.7533 of 5 stars$2.98+1.4%$28.50+856.4%+20.5%$50.83MN/A-1.482ZIVOZIVO BioscienceN/A$13.25flatN/A+18.7%$50.58M$15.85K-2.7210XCURExicure0.8054 of 5 stars$8.86+11.7%N/A+1,324.5%$50.07M$500K-2.3250News CoverageShort Interest ↑IPSCCentury Therapeutics3.3992 of 5 stars$0.58-1.0%$4.20+630.4%-74.6%$50.04M$6.59M-1.98170Positive NewsGap DownJSPRJasper Therapeutics2.7047 of 5 stars$3.21-3.6%$29.75+826.8%-83.4%$50.02MN/A-0.6120 Related Companies and Tools Related Companies ATNM Competitors PDSB Competitors ANVS Competitors DTIL Competitors SNTI Competitors NRXP Competitors ZIVO Competitors XCUR Competitors IPSC Competitors JSPR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NXTC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
